Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after combination therapy (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether psychological therapy changes adverse events: death ‐ at end of treatment (secondary outcome) compared with usual care and/or attention control (very low certainty).
It is very uncertain whether psychological therapy changes adverse events: all ‐ other events ‐ not listed above (e.g. fall,… compared with usual care and/or attention control (very low certainty).
It is very uncertain whether psychological therapy changes adverse events: all ‐ central nervous system events (e.g. suicidal… compared with usual care and/or attention control (very low certainty).
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
d4T showed no clear difference in severe adverse events compared with AZT (low certainty).
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
TDF showed no clear difference in serious adverse events compared with AZT (high certainty).
It is very uncertain whether the intervention changes all severe adverse events (very low certainty).